Home › Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW
 

Keywords :   


Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

2015-05-19 09:30:24| Biotech - Topix.net

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease . As per the CTA filing, the intended clinical study of ALN-AAT will be performed in normal healthy volunteers, and, then, in subjects with alpha-1 liver disease.

Tags: data application files trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04New law aims to protect devices from hackers
28.04National Coalition to End Period Poverty Launched
28.04PZ Cussons To Sell St. Tropez & Aveda Launches Curl Care Line
28.04Beauty Enthusiasts Eye Burgundy Mascara
28.04Distinctive Assets Distributes Mother\'s Day in Hollywood Celebrity Gift Boxes
28.04Musk in China to discuss full self driving - reports
28.04Weekly Recap: U.K. Government Announces Plastic Wipes Ban; Unicharm Starts Selling Recycled Diaper
28.04'Buying a first home is harder when you're single'
More »